Bayers, Dual

Bayer's Dual Approval Streak and Raised Guidance Draw Fresh Price Targets From DZ Bank and Deutsche Bank

Published on 11/16/2026 at 19:30 | Editorial boerse-global.de
DZ Bank, Deutsche Bank and UBS raised Bayer price targets after Q3 2026 results, two drug approvals and higher guidance, despite a EUR 672 million quarterly loss.
Bayers, Dual, Approval, Streak, Raised, Guidance, Draw, Fresh, Price, Targets Illustration mit AI erstellt.

Bayer's autumn has been bookended by regulatory wins and improved financial expectations, and sell-side analysts are recalibrating their valuations accordingly. The most recent move came on 10 November, when DZ Bank lifted its fair value for the German life-sciences group from EUR 60 to EUR 64 while reiterating its "Buy" rating, according to media reports. The brokerage pointed to operational stabilisation, debt reduction and progress in the US litigation as the pillars behind the upgrade.

That assessment lands just days after two separate approvals expanded Bayer's pharmaceutical footprint on opposite sides of the globe. On 4 November, Chinese regulators cleared Sevabertinib as a first-line treatment for adults with advanced, HER2-mutated non-small cell lung cancer — a label confined to that patient group but notable for covering front-line use rather than later lines of therapy. In the prior week, the company had announced US approval for Sunharbo, whose active ingredient is Asundexian. The FDA authorised the drug to lower the risk of further strokes in certain adults who have suffered an ischaemic stroke or a high-risk TIA, for use in combination with an antiplatelet agent. Bayer described Sunharbo as the first approved factor XIa inhibitor.

Guidance Raised Despite a Quarterly Loss

The approvals arrived alongside third-quarter 2026 results published on 3 November, when Bayer simultaneously raised its full-year outlook for EBITDA before special items and free cash flow, and lifted its margin expectations for the Pharmaceuticals division. Group revenue for the quarter reached EUR 10.1 billion, with EBITDA before special items at EUR 1.62 billion. The bottom line told a different story: a group loss of EUR 672 million. Free cash flow was negative at minus EUR 293 million, and net financial debt stood at EUR 31.1 billion. Management nonetheless projected a lower net financial debt figure going forward.

Should investors sell immediately? Or is it worth buying Bayer?

The litigation overhang remains part of the conversation. Handelsblatt framed Bayer on Saturday as a company with recent positive news while pointing to the glyphosate dispute, citing a settlement sum of USD 7.25 billion provided by Bayer.

A Cluster of Target Hikes

DZ Bank is not alone in turning more constructive. Deutsche Bank Research raised its price target from EUR 60 to EUR 65 last week and maintained its buy recommendation, crediting the strength of the pharma division and higher earnings estimates. Analyst Virginie Boucher-Ferte lifted her forecasts for EBITDA and earnings per share for 2027 and 2028. UBS, meanwhile, moved its target from EUR 62 to EUR 66 on 4 November, also confirming a buy rating and citing the strong third-quarter performance of the pharmaceuticals business.

Investors will get the next hard data point on 24 February 2027, when Bayer is scheduled to report fourth-quarter 2026 financial results.

Ad

Bayer Stock: New Analysis - 16 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70522339 |